Do Flame Retardants Promote Vitamin D Deficiency? by Petteruti, Audrey
University of New Hampshire
University of New Hampshire Scholars' Repository
Honors Theses and Capstones Student Scholarship
Spring 2014
Do Flame Retardants Promote Vitamin D
Deficiency?
Audrey Petteruti
University of New Hampshire - Main Campus, arc63@wildcats.unh.edu
Follow this and additional works at: https://scholars.unh.edu/honors
Part of the Molecular, Genetic, and Biochemical Nutrition Commons
This Senior Honors Thesis is brought to you for free and open access by the Student Scholarship at University of New Hampshire Scholars' Repository.
It has been accepted for inclusion in Honors Theses and Capstones by an authorized administrator of University of New Hampshire Scholars'
Repository. For more information, please contact nicole.hentz@unh.edu.
Recommended Citation
Petteruti, Audrey, "Do Flame Retardants Promote Vitamin D Deficiency?" (2014). Honors Theses and Capstones. 209.
https://scholars.unh.edu/honors/209
 Spring 14 
Do Flame Retardants Promote Vitamin D Deficiency?	  
Audrey Petteruti 
Senior Honors Thesis 
Biomedical Science – PreMed/PreVet 
 
Advisor: Dr. Gale B. Carey 
Professor of Nutrition 
Department of Molecular, Cellular and Biomedical Sciences 
University of New Hampshire 
 
Durham, NH 




Vitamin D deficiency in the Unites States has become more prevalent in recent years. 
Research has shown that environmental chemicals such as flame-retardants induce 
hepatic enzymes in the cytochrome P450 family such as CYP24 and CYP3A that are 
important in vitamin D metabolism. To determine if exposure to one class of flame-
retardants known as polybrominated diethyl ethers (PBDEs) promotes vitamin D 
deficiency, 15 rats consumed a diet marginally deficient in Vitamin D - 85 IU Vitamin 
D/kg diet - for 56 days. On day 28 of the experiment, 7 rats were gavaged daily with 7 
mg/kg BW PBDEs and 8 rats were gavaged daily with corn oil, for 28 days. Body weight 
and food intake were measured three times a week, vitamin D status markers in the urine 
were measured at weeks 4 and 8 and blood Vitamin D metabolites along with liver 
weight were measured at euthanization. Liver microsomal vitamin D metabolism, 
composition and CYP3A enzyme activity were also measured. The final body weight 
tended to be lower in the treatment animals than in the control but was not significantly 
different (370.29±40.12 vs. 400.63±31.99, respectively, p = 0.0636). Liver from PBDE-
treated rats was significantly heavier than liver from control rats (15.67±1.99 vs. 
12.71±0.98, respectively) p < 0.05. Liver as a percent of body weight was also 
significantly greater in treatment (4.24±0.2) compared to control (3.18±0.13). There was 
no significant difference in the lipid composition of the liver or urine metabolites 
between PBDE-treated and control rats. The inactive metabolites 24, 25-dihydroxy 
vitamin D3 and 4β, 25-dihydroxy vitamin D3 did not show significant difference between 
control and treatment groups. The active form of 1, 25-vitamin D3 tended to be lower in 
the PBDE-treated rats than in the control (0.071±0.027 vs. 0.082±0.018, respectively, p = 
0.187). When expressed as a ratio to 25(OH)D3, 4β, 25-dihydroxyD3 was significantly 
lower in treatment rats compared to control (0.96±0.18 vs. 1.28±0.38, respectively) and 
1, 25-dihydroxyD3 tended to be lower in treatment compared to control (3.62±0.96 vs. 
4.44±0.97, p = 0.068). Enzymatic CYP3A levels were significantly higher in PDBE-
treated rats than in control (6.047±1.53 vs. 0.103±0.032 nmol/min/mg protein, 
respectively). The hypothesis that the induction of CYP3A by PBDEs may accelerate 
vitamin D inactivation, leading to vitamin D deficiency was not supported by the 
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INTRODUCTION 
 
Vitamin D and Health 
 
Vitamin D is an essential nutrient for humans; it is a fat-soluble seco-steroid that 
can be made by the body. The definition of “vitamin” is a substance that is vital for life 
but must be consumed in the diet because it cannot be made by the body. Even though we 
produce vitamin D, it is considered a vitamin because the body cannot make it in 
adequate amounts. Its function was first discovered during the period between 1910-1930 
as the cause of rickets in experiments with sunlight-deprived dogs.1 
Humans obtain vitamin D from three main sources: sunlight, diet and 
supplements. In most mammals, when sunlight strikes the epidermis, vitamin D3 is made 
from the UV radiation of 7-dehydrocholesterol.2 In the diet, liver, mushrooms and 
fortified milk are good sources of vitamin D. Lastly, vitamin D is available as a 
supplement in pill form, as either vitamin D3 (animal form) or vitamin D2 (plant form). 
From 2001-2006, two-thirds of the U.S. population over the age of one was 
considered vitamin D sufficient, but out of the remaining one-third, 25% of the 
population was considered at risk of inadequacy and 8% were close to deficiency.3 
Suggested reasons for this vitamin D insufficiency are the use of sunscreen, limited 
outdoor time, or poor diet. The World Health Organization has created the definition of 
the International Unit as 1.0 IU = 65 pmol of vitamin D. The Institute of Medicine (IOM) 
suggests that people from ages 1-70 need to consume 600 IU of vitamin D per day.4 This 
amount of vitamin D is needed to maintain an adequate circulating serum level of 75 
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Role of Vitamin D in the Body 
 
Many cells in the body contain the vitamin D receptor, and thus respond to 
vitamin D. The vitamin D receptor (VDR) is in the nuclear receptor family of 
transcription factors. When vitamin D binds to the receptor, it becomes a heterodimer 
with retinoid X receptor and this complex translocates to the nucleus and binds to 
response elements that effect gene transcription.6 The many roles of vitamin D are not 
entirely understood. Active vitamin D (1, 25-dihydroxy vitamin D3) has been found to 
stimulate certain cells of the immune system, while the absence of vitamin D stunts 
growth, impairs bone development, increases insulin production and increases the risk of 
heart disease and cancer.7 It is thought that 900 genes respond directly to active vitamin 
D, primarily the genes for osteocalcin, osteopontin, calbindin, and calcium channels that 
play key roles in the control of calcium and skeletal homeostasis. The majority of VDR is 
expressed in the gastrointestinal tract and the kidneys.8 
The most widely accepted and supported role of vitamin D is its relationship with 
calcium and bone health. Calcium is essential for maintaining bone strength. Vitamin D 
facilitates the absorption of calcium in the intestines by up-regulating the calcium binding 
protein calbinin. In a severe vitamin D deficiency, calcium is not absorbed into the body 
and thus the parathyroid releases parathyroid hormone (PTH) to stimulate osteoclasts to 
break down bone and release calcium into the blood stream.9 Urinary calcium is a good 
indication of the body’s vitamin D status. High levels of urinary calcium may indicate 
that the body does not have enough or cannot utilize vitamin D to aid in calcium 
absorption. 
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Vitamin D Activation 
  
With ultra-violet B radiation, 7-dehydrocholesterol (derivative of cholesterol) 
undergoes a photoconversion to vitamin D3 or cholecalciferol in the epidermis. Once in 
the body, vitamin D circulates in the blood stream and is taken up by adipose tissue or 
liver for either further metabolism or storage lasting months or even years.10 The 
enzymes that are responsible for both the activation and inactivation of vitamin D are part 
of the cytochrome P450 family of CYP enzymes. The membrane bound CYP enzymes 
are proteins that use oxygen and NADPH to catalyze reactions for steroid hormones 
biosynthesis, bile acid biosynthesis and drug metabolism.8 The family of CYP enzymes 
used in vitamin D metabolism is located on the internal membranes of the Golgi 
apparatus and endoplasmic reticulum.  
Activation of the vitamin requires two hydroxylations, first at the C-25 site then at 
the C-1 site. Vitamin D undergoes hydroxylation in the liver, by CYP2R1 at the 25-
carbon position forming 25-hydroxy vitamin D3 or calcidiol (Figure 1). This circulating 
form of 25-hydroxy vitamin D3 reenters the blood and the majority travels to the kidneys 
where it is further metabolized through a second hydroxylation at the 1-carbon position 
by CYP27B to produce the biologically active form 1, 25-dihydroxy vitamin D3 also 
known as calcitriol.11 The biologically active form of the vitamin is found in very low 
quantities in the body, usually measured by chromatography, while the circulating 25-
hydroxyD3 is used to gauge vitamin D status.   
 
Vitamin D Inactivation 
 
In order to regulate the hormonal and nutritional functions of active vitamin D, 
the body has enzymes to inactivate both the circulating 25-hydroxyD3 and 1, 25-
dihydroxy vitamin D3. High levels of active vitamin D3 activate CYP24A1, a member of 
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the cytochrome P450 family of drug metabolizing enzymes that is involved in the 
biotransformation of more than 50% of drugs.12 CYP24A1 inactivates 1, 25-dihydroxy 
vitamin D3 by hydroxylation at the 23 and/or 24 carbon positions of the molecule to make 
1, 24, 25-trihydroxyD3 and 4β, 25-dihydroxyD3. CYP24A1 also inactivates the 
circulating form vitamin D3, 25-hydroxyD3, at the 24-carbon position to make inactive 
24, 25-dihydroxyD3 (Figure 1). In addition, another enzyme, CYP3A, can hydroxylate 
the 25-hydroxyD3 to form the inactive 24, 25-dihydroxyD3 in the liver and small 
intestines.13 Hydroxylation on the inactive metabolites causes them to become more 
water soluble for easier excretion through the bile.14 
Certain drugs such as antiepileptics have been shown to induce the CYP24 and 
CYP3A enzymes through the gene regulator PXR and ultimately decrease vitamin D3 
levels.15 The Carey lab is investigating another possible cause of increased CYP3A: 
synthetic environmental chemicals.   
 
 
Figure 1. Once ingested in the body, vitamin D3 is hydroxylated in the liver at the 25-carbon position 
(major circulating form). 25(OH)D3 is again hydroxylated in the kidney to the active 1, 25-dihydroxyD3. 
Inactivation by further hydroxylation at the 24-carbon position occurs on 1, 25-dihydroxyD3, which is 
inactivated to 1, 24, 25-trihydroxyD3 and 25-hydroxyD3 can become inactivated to 24, 25-dihydroxyD3.15 
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Flame Retardants 
 
In the past two decades, studies have revealed that environmental pollutants and 
widely used chemicals such as DDT and flame-retardants are ingested or inhaled into the 
body and are stored in adipose tissue.16 One class of flame-retardants, polybrominated 
diphenylethers (PBDEs, specifically DE-71) are additives used in chemical mixtures in 
polyurethane foams as well as many everyday appliances. These consumer products 
include coating of furniture, carpets, automobiles and airplanes that serve the purpose of 
inhibiting or delaying the spread of fire.17 In 2008, the United States, Europe and Asia 
produced 1.8 million tons of flame-retardants, equivalent to 4.25 billion US dollars.18 
Many classes of PBDE, such as DE-71 have been banned and restricted, as they are 
believed to absorb into coastal zones and remain in foods like fish and shellfish.  
As with drugs, PBDEs induce the CYP3A enzyme, which can metabolize 25-
hydroxy vitamin D3 to inactive forms. Thus the induction of CYP3A by PBDEs may 




 Pilot work from the Carey lab showed that rats fed a normal diet and given 
PBDEs did not develop vitamin D deficiency compared to rats receiving a corn oil 
control. However, normal rat diet has an abundance of vitamin D. Therefore, this work 
examined the effect of PBDEs on the vitamin D status of rats fed a diet that was 
marginally deficient in vitamin D to reflect the large portion of the U.S. population that is 
insufficient in vitamin D. It tested the hypothesis that: 
Rats fed a marginally deficient vitamin D diet and treated with flame-retardants 
will develop vitamin D deficiency.  
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METHODS 
 
This 56 day study was designed based on previous vitamin D work with rats, to 
measure the physical, biochemical and enzymatic markers of vitamin D status.  All rats 
were fed a diet marginally deficient in vitamin D for the entire duration of the 
experiment. Physical assessments included food intake, body growth, and liver weight. 
Biochemical analysis was performed on blood serum, urinary metabolites, liver 
microsomal metabolic activity and liver lipid composition. Enzymatic measurements 
included assay of the hepatic CYP3A enzyme. 
 
I. Animals and Diet 
Sixteen weaning, male Wistar rats, weighing 75-100 grams were purchased from 
Charles River Laboratories. Shortly after arrival, one rat died of unknown causes, 
determined by necropsy, and was not replaced. The remaining 15 rats were fed a diet 
containing 85 IU/kg diet vitamin D for 56 days, compared to typical diets that contain 
from 1000 to 3000 IU/kg of vitamin D. The marginal diet of 85 IU was chosen based on 
the findings of Fleet et al. that serum 25-hydroxy vitamin D3 levels are highly responsive 
to vitamin D intake between 50-200 IU/kg diet, which results in 25(OH)D3 levels ranging 
from 25-80 nmol/L (Figure 3).19 25-hydroxyD3 serum would be at the midpoint of the 
range and sensitive to changes in vitamin D status. Of the 85 IU/kg, the milk protein 
casein is responsible for 40 IU (J. Fleet, personal communication) and thus 45 IU of 
vitamin D was fortified in the diet (Figure 2).19  
Body weight and food intake of each rat was measured three times per week. All 
rats were housed individually in a controlled room at 70° F with a regular 12-hour light 
cycle with fluorescent bulbs that had GamTubeTM cover slips to block 97% UV radiation 
below 400 nm. All rats had constant access to food and water. 
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Figure 3. Effect of diets containing 25 to 1000 IU VD3/kg on serum 










Vitamin D3 IU/kg Diet 
	   9 
II. Chemicals 
DE-71 of the penta-PBDE family was donated by Dr. Mike Sanders from NIH 
and was originally produced by the Great Lakes Chemical Corporation Lot 
#1550OK07A. An amount of 2 g was dissolved in 2400 µl hexane and combined with 60 
mL of corn oil. An additional 51 ml of corn oil was added and the bottle vortexed for 30-
60 seconds. Hexane was then evaporated off with compressed nitrogen for 10 hours.20 
The original mixture of 14 mg DE-71/mL was diluted with corn oil to obtain 7 mg DE-
71/mL. The same procedure was followed for the control mixture without the addition of 
PBDE. For the duration of the experiment both bottles were stored at room temperature 
in a closed box.  
 
III. Animal Treatment 
Starting at day 28, fifteen rats were randomly assigned into control and treatment 
groups. Eight control rats were gavaged with corn oil alone and 7 rats in the treatment 
group were gavaged with 7 mg PBDE/kg BW per day.20 Gavaging is the pain-free 
procedure of scuffing and force-feeding with a ball-tipped metal syringe. The start of 
gavage was staggered so that four rats, 2 control and 2 treatment, would be euthanized on 
4 consecutive days. On day 56 of the experiment, four rats were euthanized by carbon 
dioxide inhalation after 24 hours of fasting to obtain blood and liver.  
 
IV. Assessing Vitamin D Status 
 
Urine Metabolites 
Urine was collected at 2 points during the treatment, following the procedure of 
Kurien and Schofield at 3 weeks of treatment and at the final 8th week of treatment.21 
Urine was stored at -80°C until being sent to Dr. David Collier, East Carolina University, 
for calcium and phosphorus measurements (indicators of vitamin D deficiency).  
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Measurements of creatinine were used to normalize the ratio of calcium or phosphorus 
between animals.  
Blood 
About 5.0 mL of blood was removed via cardiac puncture at euthanization using a 
5.0 mL heparinized syringe and transferred into BD VacutainerTM Serum Separation 
Tubes (Thermo Fisher Scientific). Approximately 2.5 mL of serum was collected after 
centrifugation at 3000 rpm, 23°C, for 15 minutes. Serum was stored at -80°C until being 
sent to Dr. Kenneth Thummel at the University of Washington for measurement of 25-
hydroxyD3, 24, 25-dihydroxyD3, 1, 25-dihydroxyD3 and 4β, 25-dihydroxyD3. 
 
V. Liver Microsome Preparation 
Livers were removed, rinsed, blotted and weighed before being cut into 
approximately 2.0 g portions and transported to the Carey Lab on ice or snap frozen with 
liquid nitrogen at -80°C for later use. One 2.0 g portion for each rat was minced and 
homogenized in 4 volumes of cold buffer containing 250 mM sucrose, 1 mM DTT, 0.5 
mM EDTA, 10% glycerol, 25 mM KCl, and 10 mM HEPES at pH 7.4 and centrifuged 
for 25 minutes at 20,000-x g. The pellet was discarded and the supernatant containing the 
internal membranes of the Golgi apparatus and endoplasmic reticulum (microsomes) 
were collected and buffer was added to the centrifuge tubes before ultracentrifugation at 
105,000-x g for one hour, as described by Nash et al.20 The pellet was resuspended in 
buffer and spun for a second time at 105,000-x g for one hour. The final pellet was 
resuspended in 0.1M phosphate buffer (pH 7.5) at 0.8 vol/g tissue. These microsomes 
were divided into 0.5 mL samples and were stored at -80°C until used to measure 
CYP3A and vitamin D metabolism. Microsome protein content was measured using a 
Bio-Rad protein assay kit. 
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VI. Liver Microsome CYP3A Measurements 
 
BROD Assay 
Hepatic microsomal benzyloxyresorufin O-dealkyl (BROD) activity was 
measured fluorometrically.20 Reactions were performed in a 3.0 mL cuvette starting with 
a buffer of 1.25 mL 0.2M HEPES, 250 µL of 50mM MgSO4, and 250 µL of 16 mg/mL 
BSA. Microsomes (50 µg protein) were added along with 10 µL G-6-PDH and 25 µL of 
150 µM benzoxyresorufin. The samples were brought to 2.5 mL with double distilled 
H2O and the contents were incubated for 5 minutes in low-light conditions at room 
temperature. Then the cuvette was placed in the fluorometer in no light at 37°C for 1 
minute before addition of 25 µL NADPH. The production of resorufin was measured 
fluorimetrically to analyze CYP3A activity for 5-10 minutes.  
Calculations 
The intensity of each sample in duplicate was taken for 10 points around 2 and 4 
minutes, averaged and inserted as Y (intensity) into the resorufin standard curve linear 
regression (y = 0.2708x + 1.5285) to solve for X (nM). As the cuvette contains 2.5 mL of 
solution, nM was converted to nmols by multiplying each number by 0.0025. The point at 
2 minutes was subtracted from the point at 4 and divided by 2 to obtain a rate of 
nmol/min. This number was multiplied by 20 for each sample to achieve the rate at which 
the enzyme converted 50 µg of protein in units nmol/min/mg protein. 
 
VII. Liver Microsome Vitamin D Metabolism and HPLC 
Microsomes (50 µg protein/sample) were incubated with 5.0 or 0.5 mM 25-
hydroxyD3 in 0.1M phosphate buffer, a second buffer (0.1 M KH2PO4 and 2 mM EDTA) 
and 1.0 mM NAPDH for 10, 20 or 30 minutes, following the protocol of Wang et al.22 
The contents of the incubation were extracted thrice with 0.5 mL of chloroform:methanol 
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(3:1 ratio), which causes the lipid-soluble vitamin D metabolites to become soluble in the 
organic phase, and transferred to screw-cap test tubes. The tubes were vortexed for 5 
seconds and allowed to separate into two layers. From each tube, 1.0 mL of the bottom 
layer of chloroform was removed and put into a second tube. The organic phase was 
evaporated to dryness with N2 gas, wrapped in tinfoil and stored at 4°C.  
In Dr. Curran-Celentano’s laboratory at UNH, high performance liquid 
chromatography (HPLC) analysis was performed on an Agilent 1100 series HPLC 
system equipped with a diode array detector (Agilent Technologies, Santa Clara, CA). 
The residue from the screw-cap test tubes was solubilized with 200 µl methanol and a 5.0 
µl aliquot was injected into a Symmetry C8 (2.1 X 150 mm, 3.5 µm) column (Waters, 
Milford, MA) at 25°C to separate out the peaks of interest via a linear gradient mobile 
phase as follows: 0 to 40 minutes, 70-80% methanol; 40.1 to 48 minutes, 90% methanol; 
and 48.1-63 minutes, 70% methanol. Peaks were monitored and compared to standards at 
265 nm in order to measure 25-hydroxyD3 and the inactive form of 24, 25-dihydroxyD3 
as described by Wang et al.22  
 
VIII. Lipid Extraction from Liver 
The experiment was run in triplicate using 3, 50 mg samples from each liver 
following the procedure of Li et al.23 The liver samples were weighed out and recorded, 
then homogenized in 0.3 mL of cold phosphate buffer saline at pH 7.4. The homogenate 
was mixed with 2.0 mL of 3:2 hexane/isopropanol solution, gassed with nitrogen to help 
prevent oxidation, and sealed with a rubber stopper. The sample was shaken at 23°C for 1 
hour, after 0.6 mL of 0.5 M sodium sulfate solution to remove any non-lipids. The 
sample was vortexed for 1 minute and then shaken at 23°C for 15 minutes. Then, the 
sample was centrifuged at 1000xg (~2700 rpm) for 10 minutes at room temperature. A 
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1.0 mL sample of the hexane supernatant (the upper most phase) containing lipids was 
removed and transferred to a pre-weighed and recorded tube, then dried with nitrogen gas 
for 20 minutes. Once dried, the tube containing lipids was weighed and recorded 
immediately and once more 24 hours later. 
 
IX. Data Analysis 
A t-test was performed for the main effect of rat PBDE treatment on urinary calcium, 
urinary phosphorus, blood vitamin D levels, microsomal CYP3A activity and lipid 




Animal and Liver Measurements 
 
Final body weight of the PBDE-treated rats was 7.7% lower than controls (Table 1). 
There was no difference in weight gain between treatment and control rats until day 28 
when growth of the PBDE treated rats declined by 6.9% (Figure 4). Liver weight alone 
was 23% heavier in treated rats than in control and liver weight expressed as a percent of 
body weight was 33% higher in PBDE-treated rats compared to controls (Table 1). There 
was no significant difference in the percent lipid composition of the control and treated 
livers. 
 
 Control Treatment P-value 
Final Body Weight (g) 401 ± 32 370 ± 40t 0.0636 
Weight Gain After Day 28 (g) 127.38 ± 12.85 118.57 ± 17.04 0.275 
Final Liver Weight (g) 12.71 ± 0.98 15.67 ± 1.99* 0.0012 
Liver Weight as a % of BW 3.18 ± 0.1 4.24 ± 0.2* 0.0001 
% Lipid Composition of Liver 4.55 ± 1.85 5.23 ± 2.28 0.275 
Table 1. Physiological findings of 15 rats on a marginally deficient vitamin D diet after 56 days.  Values 
are means + standard deviation.  
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Figure 4. Average weight gain of control and treatment animals over 56 days on 85 IU/kg BW marginal 
diet of vitamin D. Black arrow indicates start of PBDE chemicals at day 28 of experiment.  
 
 
Urine Metabolite Measurements 
 
There was no significant alteration in urinary calcium or phosphorus between PBDE-
treated and control groups at 4 or 8 weeks (Table 2). The calcium to creatinine ratio in 
control rats at 4 week tended to be lower than at 8 weeks (p=0.147). There was 
significant animal-to-animal variation in urinary calcium and phosphorus, as illustrated 
by standard deviation ranging from 50-143% of the mean.  
 Control Treatment 
Week 4   
Calcium/Creatinine 0.154 ± 0.144  0.171 ± 0.145 
Phosphorus/Creatinine 0.546 ± 0.696 0.476 ± 0.681 
Week 8   
Calcium/Creatinine 0.087 ± 0.032  0.136 ± 0.181 
Phosphorus/Creatinine 0.438 ± 0.292 0.451 ± 1.171 
Table 2. Urine metabolites during collection at week 3 immediately before PBDE treatment and week 8 at 




















Weight Gain Over 56 Days 
Control 
Treatment 




There was no difference in serum levels of inactive 24, 25-dihydroxyD3 and 4β, 25-
dihydroxyD3 in PBDE-treated versus control. However, active 1, 25-dihydroxyD3 level 
tended to be 13.4% lower in PBDE-treated versus control (Table 3). When each animal’s 
metabolites were expressed as a ratio to storage 25-hydroxyD3, inactive metabolite 4β, 
25-dihydroxyD3 was 25% lower than control (p < 0.05) and active form 1, 25-





Control Treatment P-value 
24, 25 D3 0.794 ± 0.130 0.781 ± 0.332 0.462 
4β, 25 D3 0.023 ± 0.003 0.19 ± 0.010 0.373 
1, 25 D3 0.082 ± 0.018 0.071 ± 0.027 0.181 
25 D3 1.740 ± 0.152 1.896 ± 0.678 0.282 






Control Treatment P-value 
24, 25 D3 42.77±8.43 38.83±10.33 0.225 
4β, 25 D3 1.28±0.38 0.96±0.18* 0.033 
1, 25 D3 4.44±0.97 3.62±0.96t 0.068 
Table 4. Serum metabolites as a molar ratio to 25-hydroxy vitamin D3 
 
 
CYP Enzyme Analysis 
 
There was a significant effect of PBDE treatment on the CYP3A enzyme activity in the 
liver microsomes prepared from PBDE-treated rats (Figure 5). After 28 days of treatment, 
the treatment CYP3A activity of 6.047 nmol/min/mg protein was greater by 59 fold (p < 
0.05) than the control activity of 0.103 nmol/min/mg protein. 
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Figure 5. Hepatic CYP3A activity of control and PBDE-treated rats on a diet marginally deficient in 




Vitamin D Metabolism 
 
A standard chromatograph of 50 minutes shows three peaks of vitamin D metabolites: 1, 
25-dihydroxyD3 and 24, 25-dihydroxyD3 both occurring mid-elusion with the larger peak 
of 25-hydroxyD3 appearing at 40 minutes (Figure 6). Positive control samples containing 
no microsomes at 10 min (samples 1, 2) versus no microsomes at 30 min (samples 9, 10) 
show a 31.6% loss in total 25-hydroxyD3 in the vial after 30 minutes of incubating. There 
was no production of the 24, 25-dihydroxyD3 or 1, 25-dihydroxyD3 metabolites for 
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1 - no microsomes (10 min) 14.49 
2 – no microsomes (10 min) 12.14 
3 - T4 (10 min) 6.39 
4 - T4 (10 min) 13.08 
5 - T4 (20 min) 5.59 
6 - T4 (20 min) 5.77 
7 - T4 (30 min) 8.31 
8 - T4 (30 min) 8.29 
9 - no microsomes (30 min) 9.77 
10 - no microsomes (30 min) 8.45 
11- T1 (30 min) 6.82 
13 - C1 (30 min) 8.41 
14 - C1 (30 min) 6.43 
15 - C3 (30 min) 5.29 
16 - C3 (30 min) 1.92 
17 - T4, no NADPH (30 min) 4.03 
18 - T4, no NADPH (30 min) 2.47 
19 - C3, no NADPH (30 min) 1.82 
20 - C3, no NADPH (30 min) 5.25 
Table 5. Total amount of vitamin D 25(OH)D3 in 2 control and 2 treatment samples analyzed by HPLC out 
of 16 nmol of 25(OH)D3. Note: there is no sample 12 due to experimental error.  
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DISCUSSION 
 
 The purpose of this study was to explore the in vivo effects of a commercial 
PBDE flame retardant mixture of DE-71 on the hepatic CYP3A enzyme responsible for 
the metabolism of drugs and inactivation pathways in the metabolism of vitamin D. The 
hypothesis that the induction of CYP3A by PBDEs may accelerate vitamin D 
inactivation, leading to vitamin D deficiency was not supported by the findings, as there 
was no significant change in serum vitamin D levels in the PBDE-treated rats.  
In contrast to our hypothesis, the measured serum metabolites of vitamin D did 
not show any difference between the control and treatment groups. A drop in the 4β-
dihydroxyD3 and especially the 24, 25-dihydroxyD3 was expected in the treatment rats 
due to the induction and up-regulation of the CYP3A, which causes the formation of 
these metabolites. Instead, the 1, 25-dihydroxyD3 active form of vitamin D was slightly 
decreased by 13.4% in the treatment rats indicating that the active hormone form of the 
vitamin was being used for unknown purposes in the treatment rats. Taking the active and 
inactive metabolites for each rat and putting them into a ratio over the storage form of the 
vitamin 25-dihydroxyD3 explored a possible mechanism for the explanation of serum 
metabolites findings. The 4β, 25-dihydroyxD3 inactive metabolite measured in the 
control rats came from the 25-dihydroxyD3 more than the rats treated with flame 
retardant. The active form tended to originate from the 25-hydroxyD3 more in the control 
group than treatment. It is possible that the difference between the two groups can be 
accounted for with another inactive metabolite 1, 24, 25-trihydroxyD3 that is produced by 
the enzyme CYP24 in the kidney and was not measured in this study.  
In agreement with the findings of Nash et al., the CYP3A enzyme was 
significantly induced by the presence of the DE-71 flame-retardant. This indicates that 
there was a greater amount of CYP3A present in the microsome samples of the treatment 
	   19 
group due to transcriptional induction. However, although it is up regulated, no 
conclusion can be made as to the activity of this enzyme in deactivating vitamin D. The 
CYP3A enzyme itself has many isomers in humans as well as rats, which implies that the 
CYP3A enzyme responsible for the inactivation of vitamin D may not be the enzyme 
analyzed and assayed in this experiment.24 Thus, multiple enzyme assays on different 
isomers and the possibly an assay on the CYP24 enzyme shown to inactivate the 1, 25 
dihydroxyD3 into the metabolite not measured in this study (1, 24, 25-trihydroxyD3) 
would need to be executed to validate the difference between rat and human enzyme 
isomers. 
Although serum levels of vitamin D did not decrease in PBDE-treated rats, the 
physiological effects of PBDEs were evident in the enlarged livers and stunted growth of 
the treatment rats. When comparing the liver as a percentage of the final body weight, the 
rats treated with PBDEs have livers that make up a significantly larger portion of their 
body weight. Previously in our laboratory, a summer research project using the same 
model rat and a higher dosage of flame-retardant (14 mg DE-71/mL) did not show a 
difference in liver or body weights of the treated animals. This indicates that the 
combination of PBDE treatment along with an induced marginal deficiency in vitamin D 
has repercussions on liver size and body weight. An extended study would need to be 
performed in order to gain any significant validation on the growth and development of 
marginally deficient rats treated with PBDEs.  
The HPLC results indicate that there was no production of the expected inactive 
24, 25-dihydroxyD3 metabolite. Although the peak appears in the standard curve, it is 
possible that amounts of this metabolite in the samples were under the detection level and 
thus no peak was seen. Since the positive controls of the samples containing no 
microsomes degraded over the course of the experiment, the data collected from the 
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samples is not considered reliable and the procedure will need further modification to 
adjust for the degradation of total 25(OH)D3 in the vials.  
This experiment is the first to examine low PBDE level exposure in addition to a 
marginal diet of vitamin D. Extending the findings to fully determine the composition of 
the enlarged treatment livers and a possible connection to Non-Alcoholic Fatty Liver 
Disease (NAFLD) could have important implications to low vitamin D levels. Further 
experimentation is needed to expand our understanding of the in vivo mechanisms of the 
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